Comprehensive Care for Pancreatic Cancer

Pancreatic cancer treatment depends on the type and stage of the disease, its relationship to nearby blood vessels and organs, and the patient’s overall health. Options may include surgery, chemotherapy, radiation therapy, and selected targeted or immune-based treatments. At Saint John’s Cancer Institute, multidisciplinary evaluation helps determine how these approaches may be used individually or together.
Our team brings together specialists in pancreatic and gastrointestinal surgery, medical oncology, radiation oncology, diagnostic imaging, pathology, and supportive care. Treatment planning considers the possibility of removing the cancer surgically, the need for systemic therapy, and the importance of maintaining nutrition, managing symptoms, and supporting quality of life.
Understanding Pancreatic Cancer Treatment
Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer and often requires more than one type of treatment. Some tumors are diagnosed when they can be removed surgically, while others involve nearby blood vessels or have spread beyond the pancreas. Treatment recommendations depend on whether the cancer is considered resectable, borderline resectable, locally advanced and unresectable, or metastatic. These categories help guide whether surgery, systemic therapy, radiation, or a combination is most appropriate.
Patients with resectable pancreatic cancer may undergo surgery followed by chemotherapy, although treatment before surgery is increasingly considered in selected situations. Borderline resectable tumors often require chemotherapy before an operation is attempted. For locally advanced or metastatic disease, systemic treatment generally plays a central role, with surgery or radiation considered according to the circumstances. Pancreatic neuroendocrine tumors differ biologically from pancreatic ductal adenocarcinoma and may require substantially different treatment approaches.
A multidisciplinary evaluation brings together imaging, pathology, laboratory findings, and other clinical information to develop an individualized plan. Pancreas-protocol CT, MRI, endoscopic ultrasound, and biopsy may help establish the diagnosis and determine whether major blood vessels or other organs are involved. In selected patients, genetic and molecular testing may identify inherited risks or tumor characteristics relevant to treatment.

Important considerations include:
- The type and location of the pancreatic tumor
- Whether the cancer can be safely removed surgically
- Involvement of nearby arteries, veins, lymph nodes, or distant organs
- The patient’s overall health, nutritional status, and existing medical conditions
- Potential benefits and risks of chemotherapy, surgery, and radiation
- Genetic or molecular findings that may influence treatment selection
- The patient’s preferences, priorities, and treatment goals
Why Treatment Sequence Matters
Pancreatic cancer can require treatment throughout the body even when imaging identifies a tumor confined to the pancreas. Microscopic cancer cells may be present beyond the visible tumor, which is one reason chemotherapy is frequently recommended in addition to surgery. Treatment given before surgery is called neoadjuvant therapy, while treatment given afterward is called adjuvant therapy. Each approach has potential benefits and limitations that depend on the individual’s diagnosis.
For some patients, chemotherapy before surgery helps address cancer cells that may have spread beyond the pancreas and provides an opportunity to assess treatment response. For others, surgery may be the appropriate initial step, followed by chemotherapy during recovery. Patients with locally advanced disease may undergo reassessment after systemic therapy to determine whether surgical removal has become feasible.
For a broader explanation of pancreatic cancer types, symptoms, diagnostic testing, and staging, visit our Pancreatic Cancer Conditions page.
Pancreatic Cancer Treatment
Treatment for pancreatic cancer may involve surgery, chemotherapy, radiation therapy, targeted medications, or supportive care. The recommended approach depends on the tumor’s location, stage, biological characteristics, and the patient’s overall health. Some treatments are intended to remove or control cancer that remains localized, while others act throughout the body or help relieve symptoms. Pancreatic cancer treatment often involves a carefully planned sequence of multiple therapies.
Pancreatic Cancer Surgery
Surgery offers an opportunity for long-term disease control or cure in selected patients whose pancreatic cancer can be completely removed. Because the pancreas lies close to major blood vessels, bile ducts, the stomach, and the small intestine, the feasibility of an operation depends on more than tumor size alone. Surgeons assess whether the cancer can be removed safely, whether nearby vessels require reconstruction, and whether the patient can tolerate a complex abdominal operation.
Pancreatic operations may be performed through traditional open surgery or, in appropriately selected patients, using minimally invasive laparoscopic or robot-assisted techniques. These approaches can offer recovery advantages in certain circumstances, but the choice depends on tumor anatomy, surgical complexity, and the need for safe cancer removal. Surgical experience and coordinated postoperative care are important considerations because pancreatic operations can involve significant technical and recovery challenges.
Whipple Procedure (Pancreaticoduodenectomy)

The Whipple procedure, also called pancreaticoduodenectomy, is the principal operation for selected cancers located in the head of the pancreas. It involves removing the head of the pancreas, the duodenum, the gallbladder, and part of the common bile duct. Depending on the operation and the cancer’s location, a portion of the stomach may also be removed. Nearby lymph nodes are generally removed for examination to help determine the extent of disease.
After the affected structures are removed, the surgeon reconstructs the digestive tract by connecting the remaining pancreas, bile duct, and stomach to the small intestine. These connections allow food, bile, and pancreatic enzymes to enter the digestive system, although digestion may function differently after surgery. The Whipple procedure is a complex operation because it involves several organs, major blood vessels, and multiple reconnections within a relatively small anatomical region.
Patients may be candidates for a Whipple procedure when imaging suggests that the cancer can be removed completely and the benefits of surgery outweigh its risks. Some patients receive chemotherapy before the operation, particularly when the tumor is considered borderline resectable or other high-risk features are present. In selected circumstances, reconstruction of nearby blood vessels may also be necessary. An experienced pancreatic surgical team evaluates these factors before recommending an operation.
Recovery involves monitoring for complications such as bleeding, infection, delayed stomach emptying, leakage from surgical connections, or pancreatic fistula. Some patients experience changes in appetite, digestion, or blood sugar regulation and may need pancreatic enzyme replacement or other nutritional support. The length of hospitalization and recovery varies considerably according to the procedure, the patient’s condition, and whether complications occur.
Distal Pancreatectomy
Distal pancreatectomy removes the body and tail of the pancreas and is generally considered for tumors located in these regions. When performed for pancreatic ductal adenocarcinoma, removal of the spleen is often necessary to achieve appropriate cancer clearance and lymph node evaluation. The exact extent of surgery depends on tumor location, involvement of nearby structures, and the underlying diagnosis. Some distal pancreatectomies can be performed using minimally invasive techniques in appropriately selected patients.
After surgery, patients may experience changes in digestive enzyme production or blood sugar control because part of the pancreas has been removed. Individuals undergoing splenectomy also require specific preventive care, including appropriate vaccinations and education about infection risks. Follow-up considers recovery, pathology findings, nutritional status, and whether additional systemic treatment is recommended.
Total Pancreatectomy
Total pancreatectomy involves removing the entire pancreas, generally along with the duodenum, gallbladder, spleen, and portions of the biliary or digestive tract, depending on the procedure. It may be considered for selected patients with tumors involving extensive portions of the pancreas, multifocal disease, or other circumstances in which a partial resection would not provide adequate treatment. It is not routinely performed for every advanced pancreatic cancer diagnosis.
Because the pancreas produces both insulin and digestive enzymes, total pancreatectomy creates lifelong insulin-dependent diabetes and pancreatic enzyme insufficiency. Patients require insulin therapy, pancreatic enzyme replacement, nutritional guidance, and ongoing medical follow-up. These permanent changes make careful preoperative counseling essential when comparing total pancreatectomy with other treatment approaches.
Palliative Procedures for Obstruction
Some pancreatic tumors obstruct the bile duct or prevent food from passing normally from the stomach into the small intestine. When cancer cannot be removed safely, procedures may be recommended to relieve these symptoms and improve comfort or nutritional intake. Endoscopic placement of a bile duct stent can help relieve jaundice caused by obstruction, while selected patients may benefit from a duodenal stent or a surgical bypass procedure.
These procedures are intended primarily to restore function and relieve symptoms rather than eliminate the underlying cancer. The choice between endoscopic, radiologic, and surgical approaches depends on the location of the obstruction, the patient’s condition, expected treatment needs, and available procedural options.
Chemotherapy for Pancreatic Cancer
Chemotherapy uses medications that circulate throughout the bloodstream to treat cancer cells. It plays an important role in pancreatic ductal adenocarcinoma because cancer cells may exist beyond the visible tumor even when the disease appears localized. Chemotherapy may be given before surgery, after surgery, or as the primary treatment for locally advanced or metastatic cancer. Its role and timing depend on resectability, overall health, previous treatment, and the patient’s ability to tolerate therapy.
Common treatment regimens include modified FOLFIRINOX and gemcitabine-based combinations, such as gemcitabine with nab-paclitaxel. NALIRIFOX is another multidrug regimen used for selected patients with metastatic pancreatic adenocarcinoma. These combinations differ in their effectiveness, side effects, and suitability for particular patients. Chemotherapy can cause fatigue, nausea, lowered blood counts, neuropathy, and other complications, making symptom management and monitoring important parts of treatment.
For patients whose cancer is removed surgically, postoperative chemotherapy can reduce recurrence risk and improve long-term outcomes. Patients with advanced disease may receive systemic therapy to control cancer growth, manage symptoms, and preserve quality of life. Treatment plans are reassessed through imaging, laboratory tests, and evaluation of treatment tolerance.
Radiation Therapy for Pancreatic Cancer

Radiation therapy uses focused high-energy radiation to damage cancer cells. It may be considered for selected patients with borderline resectable or locally advanced pancreatic cancer, sometimes in combination with chemotherapy. Radiation may also help control localized symptoms, including pain associated with tumor involvement of nearby nerves or structures. It is not required for every patient undergoing pancreatic cancer treatment.
Modern radiation techniques include intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and, in selected circumstances, stereotactic body radiation therapy (SBRT). These approaches use computerized planning and imaging to deliver treatment while managing exposure to nearby organs such as the stomach, duodenum, bowel, and kidneys. The radiation dose, number of treatments, and treatment sequence depend on the clinical situation and the objectives of care.
Targeted Therapy, Immunotherapy, and Molecular Testing
Genetic and molecular testing can identify inherited mutations or tumor characteristics that influence pancreatic cancer treatment. Germline testing evaluates inherited cancer-predisposition genes, while tumor molecular testing examines alterations within the cancer itself. These results may help identify treatment options, inform clinical trial eligibility, and provide important information for family members.
Some patients with pancreatic ductal adenocarcinoma have inherited or tumor-associated changes involving genes such as BRCA1, BRCA2, or PALB2, which can influence sensitivity to certain chemotherapy approaches. Selected patients with inherited BRCA mutations and metastatic disease that has responded to platinum-based chemotherapy may be eligible for maintenance treatment with a PARP inhibitor. Other uncommon molecular findings, including particular gene fusions or mismatch repair deficiency, may support targeted treatment or immunotherapy in appropriately selected patients.
Immunotherapy is not an established routine treatment for most pancreatic ductal adenocarcinomas, which often do not respond to currently available immune checkpoint inhibitors. Its use depends on specific tumor characteristics, approved indications, and other clinical factors. Pancreatic neuroendocrine tumors have different systemic treatment options, reinforcing the importance of establishing the correct tumor type before treatment begins.
Pain Management and Supportive Care
Pancreatic cancer can cause pain, impaired digestion, weight loss, nausea, fatigue, and changes in blood sugar regulation. These problems may result from the cancer itself, obstruction of digestive structures, or the effects of treatment. Supportive care addresses these symptoms alongside cancer-directed therapies and can help patients maintain strength, comfort, and daily function.
Pain management may involve medications, radiation therapy in selected circumstances, or procedures targeting nerves that transmit pain from the pancreas. A celiac plexus block or neurolysis can provide relief for some patients with difficult-to-control pancreatic cancer pain. These interventions are usually performed using imaging or endoscopic ultrasound guidance and are considered according to the patient’s symptoms and treatment goals.
Pancreatic enzyme replacement may help patients who cannot adequately digest food because of pancreatic insufficiency. Nutrition specialists may recommend adjustments to meals, oral supplements, or additional feeding support when necessary. Palliative care can also assist with emotional health, symptom control, treatment decisions, and practical needs at any stage of cancer, including while patients continue receiving chemotherapy or other treatment.
Clinical Trials for Pancreatic Cancer
Clinical trials evaluate new approaches to pancreatic cancer treatment, including investigational medications, combinations of established therapies, and strategies guided by molecular testing. A trial may be considered at different stages of disease, depending on the study’s purpose and eligibility requirements. Participation is voluntary, and patients should discuss the potential benefits, risks, and alternatives with their care team.
Questions to Ask Your Pancreatic Cancer Team
Pancreatic cancer treatment decisions can be complex, particularly when surgery and systemic therapy must be coordinated. Patients may find it helpful to prepare questions before an appointment and bring a family member or trusted person to help remember the discussion. With the care team’s permission, recording the conversation may also make it easier to review important details afterward.
What Type of Pancreatic Tumor Do I Have?
Pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumors, and other less common pancreatic lesions require different treatment approaches. Patients should understand what testing has established the diagnosis and whether additional pathology review, genetic testing, or molecular testing is appropriate.
Can My Cancer Be Removed Surgically?
The answer depends on tumor location, involvement of nearby blood vessels, evidence of spread, and overall health. Patients can ask whether the tumor is considered resectable, borderline resectable, locally advanced, or metastatic, and how that classification affects the treatment plan.
Should I Receive Chemotherapy Before or After Surgery?
Some patients benefit from chemotherapy before an operation, while others undergo surgery first and receive chemotherapy afterward. The treatment team can explain why a particular sequence is recommended and whether the plan may change according to treatment response.
How Will Treatment Affect My Digestion and Quality of Life?
Pancreatic surgery and systemic treatment can affect eating, digestion, blood sugar control, and daily activities. Patients can ask about pancreatic enzyme replacement, nutritional support, pain management, expected recovery, and available assistance during treatment.
Are Genetic Testing or Clinical Trials Appropriate for Me?
Inherited genetic testing is recommended for patients with pancreatic ductal adenocarcinoma and may identify findings relevant to treatment and family cancer risk. Tumor molecular testing and clinical trial evaluation may provide additional options, depending on the diagnosis and stage of disease.

At Saint John’s Cancer Institute, pancreatic cancer treatment planning brings together specialists in surgical oncology, medical oncology, radiation oncology, gastroenterology, pathology, and supportive care. This multidisciplinary approach helps patients understand how surgery, systemic treatment, and symptom management may work together.
By considering tumor characteristics, the patient’s health and priorities, and the available treatment options, our team helps patients and families make informed decisions throughout pancreatic cancer treatment and recovery.
If you have questions regarding Pancreatic Cancer or treatment, please call today. Click here to request an appointment.
Pancreatic Cancer Doctors
Webinar on Pancreatic Cancer
Listen to Anton J. Bilchik, MD, Chief of General Surgery, Director of Gastrointestinal and Hepatobiliary Program, explain pancreatic surgery with his patient, Bonnie, a pancreatic cancer survivor. Dr. Bilchik offers key questions to ask your doctor.
Pancreatic Cancer: Answers to common questions with special guest, Bonnie, Pancreas Cancer Survivor.
